Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Up – Still a Buy?

Rapport Therapeutics (NASDAQ:RAPP) gapped up before the market opened on Friday . The stock had previously closed at $24.53, but opened at $25.62. Rapport Therapeutics shares last traded at $25.02, with a volume of 2,436 shares trading hands.

Rapport Therapeutics Stock Performance

The stock’s 50-day moving average is $21.90.

Rapport Therapeutics (NASDAQ:RAPP) last released its earnings results on Thursday, August 8th. The company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($0.68) by ($1.02). Equities analysts expect that Rapport Therapeutics will post -3.46 EPS for the current fiscal year.

Institutional Investors Weigh In On Rapport Therapeutics

Institutional investors have recently bought and sold shares of the stock. Values First Advisors Inc. purchased a new position in Rapport Therapeutics in the 3rd quarter worth approximately $31,000. SG Americas Securities LLC purchased a new position in shares of Rapport Therapeutics in the third quarter worth $101,000. Sandia Investment Management LP purchased a new position in shares of Rapport Therapeutics in the second quarter worth $116,000. Davidson Kempner Capital Management LP bought a new stake in Rapport Therapeutics during the 2nd quarter valued at $229,000. Finally, Squarepoint Ops LLC purchased a new stake in Rapport Therapeutics during the 2nd quarter valued at $380,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.